Considering the alternative effects that both isoforms may have on chemoresistance, altering the 3′ end processing of NEAT1 could be a potentially useful therapeutic target, as it would not only eliminate the presence of the tumour progressing NEAT1_1, but would also replace it with the tumour repressing NEAT1_2. This evidence concerns the gene NEAT1 and neoplasm.